CP-481,715 Nickel Allergy Study.

Phase 1CompletedNCT00141180

Pfizer48 enrolled

Overview

To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Dermatitis, Allergic Contact

Interventions

CP-481,715DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST. Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).

Locations (5)

Pfizer Investigational Site

Ann Arbor, Michigan, United States

Pfizer Investigational Site

New York, New York, United States

Pfizer Investigational Site

Austin, Texas, United States

Pfizer Investigational Site

Bryan, Texas, United States

Outcomes

Primary Outcomes

Effect of CP-481,715 on clinical response and cell infiltration after nickel challenge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.